SLC2A3 and neoplasm: We analyzed adoptively transferred CD45.1+ tumor infiltrating lymphocytes (TILs) on day 30 post tumor cell injection (Figure S3B) but observed no differences in percentage CD45.1 TILs out of CD8+ TILs (normalized to tumor weight, Figure S3C), nor in their expression levels of the inhibitory markers PD1 and TIM3 (Figures S3D, S3E) for GLUT3- versus MOCK-OT1 T cells.